Limits...
Clinical Experience of Patients Referred to a Multidisciplinary Cardiac Oncology Clinic: An Observational Study.

Sulpher J, Mathur S, Graham N, Crawley F, Turek M, Johnson C, Stadnick E, Law A, Wentzell J, Dent S - J Oncol (2015)

Bottom Line: The most common reasons for referral to the cardiac oncology clinic were decreased LVEF (34.6%), prechemotherapy assessment (11.9%), and arrhythmia (8.4%).The majority (331, 77.3%) of patients were alive as of January 2013, and 93 (21.7%) patients were deceased.Through regular review of cardiac oncology clinic referral patterns, management plans, and patient outcomes, we aim to continuously improve delivery of cardiac care to our patient population and optimize cardiac health.

View Article: PubMed Central - PubMed

Affiliation: The Ottawa Hospital Cancer Centre, University of Ottawa, Ottawa, ON, Canada K1H 8L6.

ABSTRACT
Cardiotoxicity is the second leading cause of long-term morbidity and mortality among cancer survivors. The purpose of this retrospective observational study is to report on the clinical and cardiac outcomes in patients with early stage and advanced cancer who were referred to our multidisciplinary cardiac oncology clinic (COC). A total of 428 patients were referred to the COC between October 2008 and January 2013. The median age of patients at time of cancer diagnosis was 60. Almost half of patients who received cancer therapy received first-line chemotherapy alone (169, 41.7%), of which 84 (49.7%) were exposed to anthracyclines. The most common reasons for referral to the cardiac oncology clinic were decreased LVEF (34.6%), prechemotherapy assessment (11.9%), and arrhythmia (8.4%). A total of 175 (40.9%) patients referred to the COC were treated with cardiac medications. The majority (331, 77.3%) of patients were alive as of January 2013, and 93 (21.7%) patients were deceased. Through regular review of cardiac oncology clinic referral patterns, management plans, and patient outcomes, we aim to continuously improve delivery of cardiac care to our patient population and optimize cardiac health.

No MeSH data available.


Related in: MedlinePlus

Maximum decrease in LVEF from baseline (N = 196).
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4537752&req=5

fig1: Maximum decrease in LVEF from baseline (N = 196).

Mentions: Cardiac outcomes are illustrated in Table 5. The majority (381, 89.0%) of patients had baseline cardiac imaging (MUGA/echocardiogram) performed prior to commencing cancer treatment. Subsequent cardiac imaging was performed at the discretion of the treating physician. A large number of patients (196, 51.4%) exhibited at least one episode of decreased LVEF from baseline. The majority (76, 38.8%) of these patients exhibited a decrease between 10% and 19.9% and 27 (13.8%) patients had a decrease in LVEF of more than 20% (Figure 1). Recovery of LVEF to baseline was seen in 55 (28.0%) patients and partial recovery was recorded in a further 16 (8.2%) patients. However, further decline in LVEF occurred in 55 (28.0%) patients. A total of 59 (30.0%) patients achieved stable LVEF with cardiac intervention. A total of 175 (40.9%) patients referred to the cardiac oncology clinic were treated with cardiac medications; 39 (22.3%) were treated with ACE inhibitors, 22 (12.6%) were treated with beta-blockers, and 24 (13.7%) were treated with both. Multiple medications were prescribed for 90 (51.4%) patients.


Clinical Experience of Patients Referred to a Multidisciplinary Cardiac Oncology Clinic: An Observational Study.

Sulpher J, Mathur S, Graham N, Crawley F, Turek M, Johnson C, Stadnick E, Law A, Wentzell J, Dent S - J Oncol (2015)

Maximum decrease in LVEF from baseline (N = 196).
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4537752&req=5

fig1: Maximum decrease in LVEF from baseline (N = 196).
Mentions: Cardiac outcomes are illustrated in Table 5. The majority (381, 89.0%) of patients had baseline cardiac imaging (MUGA/echocardiogram) performed prior to commencing cancer treatment. Subsequent cardiac imaging was performed at the discretion of the treating physician. A large number of patients (196, 51.4%) exhibited at least one episode of decreased LVEF from baseline. The majority (76, 38.8%) of these patients exhibited a decrease between 10% and 19.9% and 27 (13.8%) patients had a decrease in LVEF of more than 20% (Figure 1). Recovery of LVEF to baseline was seen in 55 (28.0%) patients and partial recovery was recorded in a further 16 (8.2%) patients. However, further decline in LVEF occurred in 55 (28.0%) patients. A total of 59 (30.0%) patients achieved stable LVEF with cardiac intervention. A total of 175 (40.9%) patients referred to the cardiac oncology clinic were treated with cardiac medications; 39 (22.3%) were treated with ACE inhibitors, 22 (12.6%) were treated with beta-blockers, and 24 (13.7%) were treated with both. Multiple medications were prescribed for 90 (51.4%) patients.

Bottom Line: The most common reasons for referral to the cardiac oncology clinic were decreased LVEF (34.6%), prechemotherapy assessment (11.9%), and arrhythmia (8.4%).The majority (331, 77.3%) of patients were alive as of January 2013, and 93 (21.7%) patients were deceased.Through regular review of cardiac oncology clinic referral patterns, management plans, and patient outcomes, we aim to continuously improve delivery of cardiac care to our patient population and optimize cardiac health.

View Article: PubMed Central - PubMed

Affiliation: The Ottawa Hospital Cancer Centre, University of Ottawa, Ottawa, ON, Canada K1H 8L6.

ABSTRACT
Cardiotoxicity is the second leading cause of long-term morbidity and mortality among cancer survivors. The purpose of this retrospective observational study is to report on the clinical and cardiac outcomes in patients with early stage and advanced cancer who were referred to our multidisciplinary cardiac oncology clinic (COC). A total of 428 patients were referred to the COC between October 2008 and January 2013. The median age of patients at time of cancer diagnosis was 60. Almost half of patients who received cancer therapy received first-line chemotherapy alone (169, 41.7%), of which 84 (49.7%) were exposed to anthracyclines. The most common reasons for referral to the cardiac oncology clinic were decreased LVEF (34.6%), prechemotherapy assessment (11.9%), and arrhythmia (8.4%). A total of 175 (40.9%) patients referred to the COC were treated with cardiac medications. The majority (331, 77.3%) of patients were alive as of January 2013, and 93 (21.7%) patients were deceased. Through regular review of cardiac oncology clinic referral patterns, management plans, and patient outcomes, we aim to continuously improve delivery of cardiac care to our patient population and optimize cardiac health.

No MeSH data available.


Related in: MedlinePlus